A Study of ARQ 171 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Listed as NCT00398840, this PHASE1 trial focuses on Cancer and remains terminated or withdrawn. Sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), it has been updated 9 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2021 — Jan 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Mar 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Feb 2017 — Mar 2017 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
For direct contact, visit the study record on ClinicalTrials.gov .